The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Targeted Delivery of Self-Complementary Adeno-Associated Virus Serotype 9 to the Brain, Using Magnetic Resonance Imaging-Guided Focused Ultrasound
Open accessAbstract
Noninvasive drug delivery to the brain remains a major challenge for the treatment of neurological disorders. Transcranial focused ultrasound combined with lipid-coated gas microspheres injected into the bloodstream has been shown to increase the permeability of the blood-brain barrier locally and transiently. Coupled with magnetic resonance imaging, ultrasound can be guided to allow therapeutics administered in the blood to reach brain regions of interest. Using this approach, we perform gene transfer from the blood to specific regions of the mouse brain. Focused ultrasound was targeted to the right hemisphere, at multiple foci, or restricted to one focal point of the hippocampus or the striatum. Doses from 5 × 10(8) to 1.25 × 10(10) vector genomes per gram (VG/g) of self-complementary adeno-associated virus serotype 9 carrying the green fluorescent protein were injected into the tail vein. A dose of 2.5 × 10(9) VG/g was optimal to express the transgene, 12 days later, in neurons, astrocytes, and oligodendrocytes in brain regions targeted with ultrasound, while minimizing the infection of peripheral organs. In the hippocampus and striatum, predominantly neurons and astrocytes were infected, respectively. Transcranial focused ultrasound applications could fulfill a long-term goal of gene therapy: delivering vectors to diseased brain areas directly from the circulation, in a noninvasive manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 5×
“In the striatum, our data indicate a preferential expression of the GFP transgene in astrocytes, as previously reported (Foust et al., 2009).”
BackgroundMethodResultInfluentialSelf-citationKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 20×
“On the basis of previous studies using AAV9-based vectors (Fu et al., 2011; Gray et al., 2011) and our expertise in MRIgFUS delivery of therapeutics to the brain (Treat et al., 2007; Jordão et al., 2010; Burgess et al., 2011), we predicted that significant gene transfer in MRIgFUS-targeted brain…”
BackgroundInfluentialAdeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299
Self-citationImmune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241
Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144 · cited 2×
“Advances in the AAV field have led to the selection of appropriate serotypes, exhibiting tropism for various organs (Pulicherla et al., 2011), and to the characterization of conditions that are important for infection efficiency (Gray et al., 2011; Dayton et al., 2012; Rapti et al., 2012).”
BackgroundDiverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101
AAV9: a potential blood-brain barrier buster
Manfredsson, F. P., Rising, A. C., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.15 · Cited by 94
Cited by
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Self-citationMainprize, T., Lipsman, N., Huang, Y., Meng, Y., Bethune, A., Ironside, S., Heyn, C., Alkins, R., Trudeau, M., Sahgal, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36340-0 · Cited by 618
Self-citationApplications of focused ultrasound in the brain: from thermoablation to drug delivery
Meng, Y., Hynynen, K., & Lipsman, N. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00418-z · Cited by 505
Self-citationScanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498
Abrahao, A., Meng, Y., Llinas, M., Huang, Y., Hamani, C., Mainprize, T., Aubert, I., Heyn, C., Black, S. E., Hynynen, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12426-9 · Cited by 476
Self-citation
Metadata
- Authors
- Thévenot, E., Jordão, J. F., O'Reilly, M. A., Markham, K., Weng, Y.-Q., Foust, K. D., Kaspar, B. K., Hynynen, K., & Aubert, I.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2012-11
- Volume
- 23
- Issue
- 11
- Pages
- 1144-1155
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2092920458
- Cited by
- 202
- References
- 13
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.